In addition, we stratified our results based on MGMT promoter status, given the prognostic importance of this molecular biomarker in glioblastoma patients.16,17 Finally, all patients in this study cohort recurred after receiving standard of care, concurrent temozolomide/radiation therapy treatment. Here, MGMT is linked to glioblastoma.